Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Immune effector cell-associated haematotoxicity after CAR T-cell therapy: from mechanism to management

8 May 2024

Abstract excerpt

Genetically engineered chimeric antigen receptor (CAR) T cells have become an effective treatment option for several advanced B-cell malignancies. Haematological side-effects, classified in 2023 as immune effector cell-associated haematotoxicity (ICAHT), are very common and can predispose for clinically relevant infections. As haematopoietic reconstitution after CAR T-cell therapy differs from...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomedical Ethics and Regulation
Share to CAR-T cell therapy research
Share to Virus-based gene therapy research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38734026
DOI: 10.1016/s2352-3026(24)00077-2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Immune effector cell-associated haematotoxicity after CAR T-cell therapy: from mechanism to managementPMID 38734026Read ↗

Prolonged Cytopenia with CAR-T Cell Therapy and Management RecommendationsSemantic proximity Read ↗

Hematopoiesis and immune reconstitution after CD19 directed chimeric antigen receptor T‐cells (CAR‐T): A comprehensive review on incidence, risk factors and current managementSemantic proximity Read ↗

Cytopenias following anti-CD19 chimeric antigen receptor (CAR) T cell therapy: a systematic analysis for contributing factorsSemantic proximity Read ↗

Distinct cellular signatures in aplastic and intermittent phenotypes of immune effector cell-associated hematotoxicity.Semantic proximity Read ↗

Overview of Adverse Events Associated With Anti-CD19 Chimeric Antigen Receptor T-Cell TherapySemantic proximity Read ↗

CAR-T Cell Therapy: Mechanism, Management, and Mitigation of Inflammatory Toxicities.Semantic proximity Read ↗

Brexucabtagene Autoleucel For Relapsed/Refractory Mantle Cell Lymphoma in Asia: Redefining the Role of Allogeneic Haematopoietic Stem Cell TransplantationSemantic proximity Read ↗

Mesenchymal stem cell infusion for enhancing hematopoietic recovery and addressing cytopenias in CAR-T cell therapySemantic proximity Read ↗

Graft‐versus‐host disease risk after chimeric antigen receptor T‐cell therapy: the diametric opposition of T cellsSemantic proximity Read ↗

Concise Review: Acute Graft-Versus-Host Disease: Immunobiology, Prevention, and TreatmentSemantic proximity Read ↗

A New Era in Endothelial Injury Syndromes: Toxicity of CAR-T Cells and the Role of Immunity.Semantic proximity Read ↗

Interferon-γ blockade in CAR T-cell therapy–associated macrophage activation syndrome/hemophagocytic lymphohistiocytosisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.